All In Biotech

Drug Trial Radar · NCT05127434

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults ≥60 Years of Age

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 36,814 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

36,814

Actual

Start

Nov 17, 2021

Primary completion

Jul 28, 2025

Study completion Jul 28, 2025

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
First posted
Nov 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single dose of mRNA-1345 vaccine in the prevention of a first episode of RSV-associated lower respiratory tract disease (RSV-LRTD) as compared with placebo from 14 days postinjection through 12 months. The main purpose of Part B of this study is to evaluate the safety, tolerability and immunogenicity of a booster dose (BD) of mRNA-1345 administered 24 months after the primary dose.

Conditions

  • Respiratory Syncytial Virus

Interventions

  • PlaceboDrug

    0.9% sodium chloride (normal saline) injection

  • mRNA-1345Drug

    Sterile liquid for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants With Any Solicited Adverse Reactions (ARs) (Solicited Local and/or Systemic ARs)Time frame: Up to 7 days postinjection
  2. Part B: Number of Participants With Solicited Local and Systemic ARsTime frame: Up to 7 days post-BD injection
  3. Part A: Number of Participants With Unsolicited Adverse Events (AEs)Time frame: Up to 28 days postinjection
  4. Part B: Number of Participants With Unsolicited AEsTime frame: Up to 28 days post-BD injection
  5. Part A: Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study DiscontinuationTime frame: Up to 24 months postinjection
  6. Part B: Number of Participants With MAAEs, AESIs, SAEs, and AEs Leading to Study DiscontinuationTime frame: Up to BD Day 181
  7. Part A: Number of Participants With Respiratory Syncytial Virus- Associated Lower RSV-LRTD With 2 or More Symptoms From 14 Days Postinjection up to 12 Months PostinjectionTime frame: From 14 days postinjection up to 12 months postinjection
  8. Part A: Number of Participants With RSV-LRTD With 3 or More Symptoms From 14 Days Postinjection up to 12 Months PostinjectionTime frame: From 14 days postinjection up to 12 months postinjection
  9. Part B: Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) and Respiratory Syncytial Virus Subtype B (RSV-B) Neutralizing Antibodies (nAb) at BD Day 29 Compared to Primary Dose Day 29Time frame: Primary Dose Day 29 and BD Day 29

Locations

269 sites in 23 countries. Site status is shown where the registry gives one.

  • AES - DRS - Synexus Clinical Research US, Inc. - Birmingham

    Birmingham, Alabama

  • Accel Research Site - Achieve - Birmingham

    Birmingham, Alabama

  • Lakeview Clinical Research

    Guntersville, Alabama

  • AES - DRS - Optimal Research Alabama - Huntsville

    Huntsville, Alabama

  • Hope Research Institute LLC - Hunt - PPDS

    Hunt, Arizona

  • Hope Research Institute LLC - Hunt - PPDS

    Hunt, Arizona

  • Desert Clinical Research, LLC - CCT

    Mesa, Arizona

  • Hope Research Institute LLC - Phoenix - Hunt - PPDS

    Phoenix, Arizona

  • AES - DRS - Synexus Clinical Research US, Inc. - Phoenix Central

    Phoenix, Arizona

  • Synexus Clinical Research US, Inc. - Phoenix Southeast

    Phoenix, Arizona

  • Tucson Neuroscience Research - M3 WR

    Tucson, Arizona

  • Baptist Health Center for Clinical Research

    Little Rock, Arkansas

  • Velocity Clinical Research, Banning

    Banning, California

  • Hope Clinical Research, LLC

    Canoga Park, California

  • Velocity Clinical Research - Chula Vista - PPDS

    Chula Vista, California

  • PPD Virtual - Science 37, Inc

    Culver City, California

  • Velocity Clinical Research, San Diego

    La Mesa, California

  • PRI, LLC - Los Alamitos - M3 WR

    Los Alamitos, California

  • PRI, LLC - Newport Beach - M3 WR

    Newport Beach, California

  • FOMAT Medical Research - FOMAT - HyperCore - PPDS

    Oxnard, California

  • Reddy Care Medical

    Pomona, California

  • Paradigm Clinical Research Institute Inc - ClinEdge - PPDS

    Redding, California

  • Medical Center For Clinical Research - M3 WR

    San Diego, California

  • Lynn Institute of Denver

    Aurora, Colorado

  • Tekton Research - Fort Collins - PPDS

    Fort Collins, Colorado

  • Tekton Research - Longmont - PPDS

    Longmont, Colorado

  • Paradigm Clinical Research Institute Inc - ClinEdge - PPDS

    Wheat Ridge, Colorado

  • Clinical Research Consultants LLC - ClinEdge - PPDS

    Milford, Connecticut

  • Washington Health Institute

    Washington D.C., District of Columbia

  • Velocity Clinical Research, New Smyrna Beach

    Edgewater, Florida

  • Fleming Island Clinical Research Center

    Fleming Island, Florida

  • Velocity Clinical Research - Hallandale Beach - PPDS

    Hallandale, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Multi-Specialty Research Associates, Inc. M3 WR

    Lake City, Florida

  • Accel Research Sites - Maitland - ERN - PPDS

    Maitland, Florida

  • Spotlight Research Center, LLC

    Miami, Florida

  • IMA Clinical Research - Manhattan - PPDS

    Miami Beach, Florida

  • AES - DRS - Synexus Clinical Research US, Inc. - The Villages

    Orlando, Florida

  • Health Awareness Inc

    Port Saint Lucie, Florida

  • IMA Clinical Research - Saint Petersburg - PPDS

    St. Petersburg, Florida

Showing 40 of 269 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.